MedPath

Comparative Study of the Efficacy of TENS Versus Placebo in Isolated Primary Enuresis

Not Applicable
Completed
Conditions
Enuresis, Nocturnal
Interventions
Other: TENS Sham
Other: TENS
Registration Number
NCT04413461
Lead Sponsor
Fondation Lenval
Brief Summary

Nocturnal enuresis is a functional urinary disorder in children. It is intermittent urinary incontinence during sleep in children aged 5 years and older. It is said to be "primary" if the child has never been clean at night for at least 6 months and "isolated" if there are no other associated urinary symptoms, including daytime symptoms.

It is a common condition with significant repercussions, including disruption of family and social life and a frequent decline in self-esteem. Without treatment, it can persist into adulthood. All these reasons justify taking care of these children.

This is usually based on:

The establishment of hygienic-dietetic rules: Regular urination and before sleeping, limitation of fluid intake in the evening. They are systematically implemented, whatever the subsequent management Drug treatments (Desmopressin, oxybutynin). These treatments have an efficiency of 60 to 70% at 6 months post treatment and sometimes have side effects.

Non-drug treatments: Night-time "pee stop" alarms. They have an efficiency of around 70%. They are little used because they often wake up the whole family and are not reimbursed by social security.

TENS (Transcutaneous Electro Neuro Stimulation) is a neuro-modulation technique which consists of stimulating the nerves by means of skin electrodes in order to obtain a somatic response.

In urology, it is mainly used by stimulating either the sacral region, origin of the vesical innervation, or the tibial nerve. Its main indication is overactive bladder, a source of discomfort and incontinence.

It is used at home, the side effects are exceptional and it does not disturb the activities of the patients.

Few studies have evaluated its effectiveness in isolated primary enuresis.

Detailed Description

Nocturnal enuresis is a functional urinary disorder in children. It is intermittent urinary incontinence during sleep in children aged 5 years and older. It is said to be "primary" if the child has never been clean at night for at least 6 months and "isolated" if there are no other associated urinary symptoms, including daytime symptoms.

It is a common condition with significant repercussions, including disruption of family and social life and a frequent decline in self-esteem. Without treatment, it can persist into adulthood.

All these reasons justify taking care of these children.

This is usually based on:

The establishment of hygienic-dietetic rules: Regular urination and before sleeping, limitation of fluid intake in the evening. They are systematically implemented, whatever the subsequent management Drug treatments (Desmopressin, oxybutynin). These treatments have an efficiency of 60 to 70% at 6 months post treatment and sometimes have side effects.

Non-drug treatments: Night-time "pee stop" alarms. They have an efficiency of around 70%. They are little used because they often wake up the whole family and are not reimbursed by social security.

TENS (Transcutaneous Electro Neuro Stimulation) is a neuro-modulation technique which consists of stimulating the nerves by means of skin electrodes in order to obtain a somatic response.

In urology, it is mainly used by stimulating either the sacral region, origin of the vesical innervation, or the tibial nerve. Its main indication is overactive bladder, a source of discomfort and incontinence.

It is used at home, the side effects are exceptional and it does not disturb the activities of the patients.

Main objective is to compare the effectiveness of treatment with TENS versus TENS sham procedure (placebo) in isolated primary enuresis, one month after the end of treatment in patients from 5 to 17 years old The effectiveness will be evaluated by the evolution of the number of wet nights

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
54
Inclusion Criteria

Children 5 to 17 years old

  • Medium or severe isolated primary enuresis (more than 1 episode per week)
  • Never treated or in failure of previous treatment (with treatment discontinuation for at least 1 month)
  • Affiliation to a social security scheme
  • Good understanding of the protocol
  • Signature of informed consent by a parent or the legal representative of parental authority
Exclusion Criteria

Other pathologies which can influence urination behavior (Daytime urinary disorders)

  • Treatment in progress which can modify voiding behavior
  • TENS treatment in progress for another pathology

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
TENS ShamTENS Sham-
TENSTENS-
Primary Outcome Measures
NameTimeMethod
effectiveness of treatment with Transcutaneous Electro Neuro Stimulation (TENS) versus TENS sham procedure at 1 month post treatmentat 2 months

The effectiveness will be evaluated by the evolution of the number of wet nights.

Measure of number of wet nights per week at baseline before treatment by TENS and at 1 month after the end of treatment

Secondary Outcome Measures
NameTimeMethod
effectiveness of treatment with TENS versus TENS sham procedure at 1 monthat 1 month

measure of number of wet nights per week at the end of treatment

quality of life during treatmentat baseline and at 1 month and at 2 month

measure of quality of life with the Pediatric Quality of Life Inventory (Peds QL) questionnaire.

The Pediatric Quality of Life Inventory (PedsQL) is a 23-items generic health status instrument with parent and child forms that assesses five domains of health (physical functioning, emotional functioning, psychosocial functioning, social functioning, and school functioning) in children and adolescents ages 2 to 18.

For ease of interpretability, items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL (Health-Related Quality of Life). The minimum value is 0 and maximum is 100.

Trial Locations

Locations (4)

CH de Cannes

🇫🇷

Cannes, France

CH de GRASSE

🇫🇷

Grasse, France

CHU de Nice

🇫🇷

Nice, France

Hôpitaux Pédiatrique de Nice CHU Lenval

🇫🇷

Nice, France

© Copyright 2025. All Rights Reserved by MedPath